IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Subscribe To Our Newsletter & Stay Updated
